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2.1.1 Clinical characteristics  Fibromyalgia	(FM)	is	a	condition	marked	by	chronic	pain	and	multiple	symptoms	of	both	somatic	and	psychological	nature.	The	predominant	feature	is	widespread	pain,	tenderness	and	stiffness	in	the	muscles,	tendons	and	ligaments,	without	any	demonstrated	tissue	abnormality.	More	specifically	patients	with	FM	have	a	decreased	pain	threshold,	which	means	that	they	display	heightened	pain	responses	to	normally	nonpainful	stimuli	(also	known	as	allodynia)	and	heightened	pain	responses	to	normally	painful	stimuli	(also	known	as	hyperalgesia).1	FM	pain	may	occur	body	wide,	migrate	over	the	body,	or	in	pre-specified	points	on	the	body	particularly	sensitive	to	pressure	(so-called	tender	points).	The	pain	often	varies	from	day	to	day	and	many	patients	report	the	pain	aggravating	by	certain	weather	conditions.2-5	Other	common	features	of	the	disorder	include	fatigue,	sleep	disturbances,	subjective	swelling,	paresthesias,	cognitive	dysfunction,	headaches	and	irritable	bowel	syndrome	(IBS),	depression	and	anxiety.6	These	symptoms	can	often	be	as	disabling	as	the	pain	itself,	and	altogether	FM	constitutes	a	plethora	of	medically	unexplained	symptoms,	not	only	causing	disability,	but	often	also	symptom-related	distress	and	avoidance	of	daily	activities.7,8	Not	surprisingly,	FM	is	associated	with	a	lower	health-related	quality	of	life,	and	the	experience	of	illness	seems	to	be	worse	compared	to	many	other	disorders.1		





2.1.3 Prevalence, comorbidity and health economic aspects Most	prevalence	studies	estimate	the	prevalence	of	FM	to	between	2%	and	4%.12	However,	the	majority	of	prevalence	studies	are	based	on	the	ACR	1990	criteria	which	have	shown	to	yield	lower	prevalence	rates	than	the	modified	2010	criteria,13,14	indicating	that	FM	might	be	more	common	than	previously	thought.	Women	seems	to	be	more	afflicted	than	men,	although	when	using	the	later	version	of	the	criteria	(i.e.,	without	tender	point	examination)	the	sex	ratio	seems	to	be	more	equal,1	however	still	with	a	predominance	in	women.	Although	being	most	common	in	patients	over	50	years	of	age,12	FM	also	occurs	in	children	and	adolescents.15	FM	has	a	high	degree	of	comorbidity.	Common	co-occurring	conditions	are	found	within	the	cardiovascular	and	respiratory	diseases	and	other	pain-related	conditions,16	and	FM	patients	also	display	a	high	rate	of	anxiety	and	depressive	disorders.17	Several	of	these	disorders	(e.g.,	chronic	fatigue	syndrome,	temporomandibular	disorder,	IBS,	migraine)	have	overlapping	symptoms	such	as	generalized	pain	sensitivity,	and	no	consistent	demonstrated	tissue	abnormality.	Observations	from	genetic	research	demonstrating	that	these	syndromes	run	in	families	suggest	that	they	share	heritable	pathophysiologic	features.18,19	 FM	is	also	a	costly	disorder.	Patients	with	FM	on	average	have	a	mean	healthcare	cost	that	is	almost	three	times	higher	than	comparison	patients.16	Being	the	chronic	pain	condition	with	the	highest	rates	of	sick-leave,	unemployment,	claims	for	incapacity	benefits	and	work	absenteeism,	FM	incurs	high	costs	also	on	a	societal	level.20,21			
	
†Diagnostic	criteria	according	to	the	2016	revisions	to	the	2010/2011	criteria.11	(1) Generalized	pain,	defined	as	pain	in	at	least	4	of	5	regions,	is	present.		(2) Symptoms	have	been	present	at	a	similar	level	for	at	least	3	months.		(3) Widespread	Pain	Index	(WPI)	≥	7	and	Symptom	Severity	Scale	(SSS)	score	≥	5	OR	WPI	of	4–6	and	SSS	score	≥	9.	(4) A	diagnosis	of	fibromyalgia	is	valid	irrespective	of	other	diagnoses.	A	diagnosis	of	fibromyalgia	does	not	exclude	the	presence	of	other	clinically	important	illnesses.	
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2.2 ETIOLOGY AND CONTRIBUTING FACTORS Available	evidence	suggests	that	FM	does	not	have	a	clear	etiology	but	may	be	caused	by	multiple	interacting	factors,	including	neurotransmitter-	and	cytokine	imbalances	in	the	central	nervous	system	(CNS),22	disturbances	in	the	hypothalamic–pituitary–adrenal	axis,23	genetic	factors24	and	psychiatric	comorbid	conditions.23	Thus,	there	seems	to	be	many	roads	that	can	lead	to	the	development	of	FM.	As	for	the	question	regarding	what	FM	actually	‘is’,	the	leading	pathophysiological	hypothesis	is	that	FM	is	a	disorder	within	the	CNS	related	to	pain	transmission	and	pain	processing1	and	that	the	CNS	has	a	leading	role	in	the	augmentation	and	amplification	of	pain	in	FM.		The	International	Association	for	the	Study	of	Pain	(IASP)	defines	pain	as	“an	unpleasant	sensory	and	emotional	experience	associated	with	actual	or	potential	tissue	damage,	or	described	in	terms	of	such	damage”.25	This	definition	highlights	the	inherent	subjective	nature	of	pain	and	fits	well	with	the	medically	unexplained	pain	that	is	the	core	feature	of	FM.	It	is	also	well	known	that	the	experience	of	pain	is	a	complex	interaction	of	biological,	psychological	and	social	factors.26	This	is	further	highlighted	below.	
2.2.1 Pain physiology in FM When	pain	occurs	as	a	consequence	of	clear	tissue	damage	or	inflammation,	signals	from	nociceptors	(pain	neurons)	are	transported	via	nerve	cells	to	the	dorsal	horn	in	the	spinal	cord,	from	which	the	information	are	further	transferred	to	the	brain.	Interestingly,	the	brain	can	also	receive	pain	signals	with	only	little	or	even	without	nociceptive	information,	meaning	that	the	patient	experiences	pain	without	tissue	damage	or	inflammatory	processes.27	This	is	the	case	in	FM	and	other	functional	pain	disorders	such	as	IBS,	functional	abdominal	pain	or	chronic	cardiac	chest	pain.	The	incoming	pain	signal	may	be	amplified	or	inhibited,	resulting	in	an	augmented	or	attenuated	pain	perception.1	In	FM,	it	seems	that	the	CNS	itself	contributes	to	an	active	amplification	of	sensory	stimuli,28,29	leading	to	an	enhanced	response	to	noxious	stimuli	as	well	as	an	intensified	excitability	of	the	neurons	in	the	spinal	cord	transmitting	nociceptive	information	to	the	brain.30	Also,	blunting	of	the	descending	inhibitory	pathways	in	FM	attenuates	the	capacity	for	the	CNS	to	achieve	brain-regulated	inhibition	of	pain	signals.31-34		Various	psychological	factors	are	also	involved	in	the	process	of	pain	amplification.	For	instance,	depressive	mood	and	anxiety	are	factors	that	have	been	shown	to	amplify	the	nociceptive	signals	in	experimental	pain.35	Also,	avoidance	behaviors	and	hypervigilance	are	two	factors	that	are	relevant	in	the	understanding	of	FM	(further	elaborated	below).		
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2.4 TREATMENT OF FM 
2.4.1 Non-psychological treatments The	pharmacological	agents	most	thoroughly	evaluated	for	treating	FM	include	antidepressants	such	as	amitriptyline,	duloxetine	and	milnacipran,	and	the	antiepileptic	
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agent	pregabalin/gabapentin.77	These	drugs	have	shown	to	have	positive	effects	not	only	on	pain	but	also	on	secondary	symptom	domains	in	FM.78	However,	the	observed	effect	sizes	of	these	drug	treatments	are	mostly	modest	and	tolerability	is	often	limited	by	side	effects.	Overall,	the	benefits	of	pharmacotherapy	in	FM	have	been	argued	to	be	of	limited	clinical	relevance.77,79		Also,	a	broad	range	of	other	non-pharmacological	treatments	have	been	evaluated	for	FM.	Examples	include	(but	are	not	restricted	to)	physical	exercise,	balneotherapy,	body	awareness	therapy,	biofeedback,	complementary/alternative	medicine	(CAM)	treatments	(e.g.,	acupuncture,	chiropractic	therapy,	homeopathy,	massage	therapy,	meditative	moment	therapies	or	mind/body-therapies),	trans-magnetic	stimulation	and	trans-direct	current	stimulation.80	A	recent	meta-analysis80	concluded	that	exercise	and	meditative	moment	therapies	may	be	beneficial	for	FM	patients.	However,	studies	are	generally	too	small	and	of	insufficient	quality,	why	no	definitive	conclusions	regarding	the	benefits	of	these	treatments	can	be	made.79,80	
2.4.2 Psychological treatments The	majority	of	psychological	treatments	evaluated	for	FM	have	been	varieties	of	cognitive	behavior	therapy	(CBT),	described	below.	Additional	psychological	interventions	evaluated	for	FM	include	mindfulness-based	interventions,81,82	short-term	psychodynamic	therapy83	and	hypnosis.84	Apart	for	a	few	exceptions	(e.g.,	attention	modification	training85)	most	of	these	studies	have	had	null	findings	or	modest	effects.	







2.5 SUMMARY OF THE BACKGROUND OF THE THESIS FM	is	a	prevalent	and	disabling	condition.	It	is	associated	with	low	quality	of	life	and	high	comorbidity	with	other	conditions,	and	is	also	a	costly	disorder	for	both	healthcare	providers	and	society.	Most	likely	the	etiology	of	FM	is	multifactorial,	i.e.,	many	roads	can	lead	to	the	development	of	FM.	Avoidance	behaviors	and	hypervigilance	are	probably	important	and	interacting	psychological	mechanisms	in	the	maintenance	of	chronic	widespread	pain,	the	main	feature	of	FM.		Altogether	the	available	evidence	suggests	that	CBT	might	have	the	potential	to	alleviate	FM	symptoms.	However,	the	overall	between-group	effect	sizes	are	low	and	the	health	economic	aspects	of	this	treatment	is	still	unclear.	Additionally,	we	still	do	not	know	what	drives	the	treatment	effect	in	the	different	CBT	protocols.	Thus,	there	is	still	a	need	for	large-scale	clinical	trials	designed	to	take	the	first	steps	in	investigating	mechanisms	and	mediators	of	treatment	outcome	in	CBT	for	FM.	Internet-CBT	could	increase	outreach	to	patients	with	FM	but	the	evidence	of	this	treatment	format	is	still	limited.			Exposure	is	a	potentially	promising	treatment	strategy,	but	a	new	approach	compared	to	previous	trials	might	yield	better	results.	A	functional	view	on	avoidance,	acknowledging	that	additional	symptoms	besides	pain	can	elicit	symptom-related	avoidance,	and	targeting	also	covert	avoidance;	open	up	for	identifying	more	relevant	avoidance	behaviors	to	target	in	treatment.				 	
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3 AIMS The	overall	aim	of	the	thesis	was	to	develop	and	evaluate	an	internet-delivered	exposure-based	treatment	for	FM.	The	premise	was	to	explore	whether	exposure	to	stimuli	associated	with	FM-related	distress	as	well	as	avoided	situations	and	activities	would	be	beneficial	for	patients	with	FM.	Specific	aims	and	hypotheses	for	each	study	are	presented	below:	
3.1 STUDY I The	aim	of	the	first	study	was	to	develop	a	first	version	of	the	treatment	protocol	and	to	evaluate	the	acceptability,	efficacy	and	health	economic	effects	of	an	internet-delivered	exposure-	and	acceptance-based	treatment	for	FM.		
3.2 STUDY II This	study	aimed	to	revise	the	treatment	protocol	and	evaluate	the	efficacy	of	internet-delivered	exposure	therapy	(iExp)	compared	to	a	waitlist	control	group	within	a	randomized	controlled	trial.	Based	on	the	results	from	Study	I,	we	hypothesized	that	the	treatment	would	be	more	effective	than	the	control	group.	
3.3 STUDY III Study	III	used	data	from	Study	II,	and	aimed	to	evaluate	the	treatment’s	cost-effectiveness	and	cost-utility.	We	hypothesized	that	iExp	would	be	cost-effective	compared	to	a	waitlist	control.	
3.4 STUDY IV Study	IV	used	data	from	Study	II,	and	sought	to	investigate	possible	mediators	of	treatment	outcome.	We	hypothesized	that	FM-related	avoidance	behaviors,	FM-related	worry	and/or	mindful	non-reactivity	would	mediate	a	change	in	FM	symptoms	for	participants	receiving	iExp	compared	to	participants	in	the	waitlist	control	group.	
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4 EMPIRICAL STUDIES 








4.3 THE INTERVENTION 





Figure 1. Screenshot of the maintenance model.
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4.3.2 Lessons learned from Study I The	starting	point	of	this	PhD	project	was	to	investigate	whether	patients	with	FM	could	benefit	from	a	treatment	focusing	on	decreasing	symptom-specific	avoidance	behaviors	and	hypervigilance	through	systematic	exposure.	We	originated	from	a	manual	that	has	shown	effective	in	IBS,105,106,128-130	a	condition	highly	comorbid	with	FM.	Early	on	we	decided	to	incorporate	elements	from	ACT	as	we	hypothesized	that	certain	ACT	interventions	(e.g.,	focusing	on	life	values)	would	increase	motivation	to	engage	in	behavior	change.		The	lessons	drawn	from	Study	I	was	that	many	participants	were	in	fact	positive	to	behavior	change	using	a	more	traditional	rationale	for	exposure	(i.e.,	using	a	maintenance	model	similar	to	the	one	used	in	the	manual	for	IBS).	Also,	a	challenge	emerged	in	delivering	the	rationale	for	values-based	action.	Several	participants	experienced	problems	in	identifying	important	life	values	and	deriving	valued	activities	that	were	independent	of	their	FM.	One	possible	explanation	could	be	that	the	introduction	to	and	exercise	in	identifying	and	mapping	life	values	were	in	the	first	module	of	treatment,	i.e.,	at	a	time	when	they	were	just	getting	acquainted	with	the	treatment	context	and	format,	and	with	a	dense	amount	of	other	concurrent	psychoeducational	material.	It	is	probably	a	fair	estimate	that	this	intervention,	when	not	delivered	within	a	full	ACT	context	(i.e.,	with	complementing	facilitating	interventions)	might	not	have	achieved	its	full	potential.		Moreover,	the	therapists	in	Study	I	found	a	challenge	in	motivating	the	participants	to	conduct	exposure	using	two	partly	differing	rationales.	In	values-based	exposure,	participants	were	first	encouraged	to	join	in	values-based	behavioral	activation,	and	later	on	to	engage	in	values-based	exposure	exercises.	In	contrast,	when	conducting	exposure	as	prescribed	originally	in	the	IBS-manual,	exercises	were	derived	from	the	participants’	symptom-specific	avoidance	behavior.	Consequently,	exercises	were	not	necessarily	associated	with	life	values	(although,	of	course,	they	could	be),	but	rather	with	the	emphasis	to	try	to	challenge	as	many	avoidance	behaviors	as	possible.	Although	the	purpose	was	to	provide	a	broader	perspective	on	behavioral	change	by	offering	two	related	yet	complementary	approaches	to	exposure,	the	impression	from	the	therapists	was	that	most	participants	found	this	confusing.		








4.4 SAFETY PARAMETERS Severe	psychiatric	conditions	requiring	immediate	intervention	were	ruled	out	before	inclusion,	via	an	online	screening	procedure	as	well	as	a	clinical	intake	interview	with	a	psychology	graduate	student	under	supervision	or	a	clinical	psychologist.	Participants	that	were	excluded	due	to	severe	depression	or	suicidal	ideation	were	recommended	to	seek	regular	psychiatric	services.	
Figure 2. Exposure worksheet in Study II. 
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In	both	Study	I	and	II,	all	participants	were	assessed	weekly	regarding	suicidal	ideation.	Any	participant	scoring	≥4	on	the	suicide	item	on	the	Montgomery-Åsberg	Depression	Rating	Scale-self	report	(MADRS-S)131	were	phoned	by	their	therapist,	who	conducted	a	comprehensive	assessment	of	immediate	suicide	risk.	If	deemed	necessary,	a	crisis	plan	was	established	together	with	the	participant.	Adverse	Events	(AE)	were	collected	in	Study	I	and	II.	Questions	regarding	AEs	were	collected	at	post-treatment,	6-	and	12-months	follow-up	(the	latter	with	Study	II	only),	with	detailed	follow-up	questions	on	any	possible	event.	All	AEs	were	assessed	by	a	clinical	psychologist,	and	if	needed	followed-up	with	a	telephone	interview.			





5.1 STUDY I 
Internet-Delivered	Acceptance	and	Values-Based	Exposure	Treatment	for	
Fibromyalgia:	A	Pilot	Study.	Post-treatment	assessments	were	completed	by	40	out	of	41	participants	(98%).	Significant	improvements	were	seen	at	all	outcomes	from	pre-	to	post-treatment	(all	ps	<.001),	and	from	pre-treatment	to	follow-up	(all	ps	<.001).	A	moderate	within-group	effect	size	was	observed	on	the	primary	outcome	(d=0.71;	95%	CI	0.46	to	0.91)	at	post-treatment,	and	looking	from	pre-treatment	to	follow-up	the	effect	size	was	large	(d=0.96;	95%	CI	0.66	to	1.27).	Thirty	out	of	41	participants	commenced	work	with	exposure,	indicating	that	the	treatment	was	acceptable.	There	were	significant	cost	reductions	both	at	post-treatment	(p=.002)	and	at	follow-up	(p=.04)	compared	to	pre-treatment.	
5.2 STUDY II 
Internet-based	Exposure	Therapy	for	Fibromyalgia:	A	Randomized	Controlled	
Trial.	All	participants	completed	the	primary	outcome	at	pre-	and	post-treatment	assessments.	On	the	primary	outcome	there	was	a	significant	interaction	effect	of	group	and	time	with	a	large	between-group	effect	size	(d=0.90;	95%	CI	0.55	to	1.24),	favoring	the	treatment	group.	In	the	iExp	group,	44%	of	the	participants	achieved	a	reliable	improvement	on	the	primary	outcome.	Significant	improvements	were	also	seen	on	all	secondary	outcomes,	the	majority	with	moderate	to	large	effect	sizes	(d=0.44	to	1.24).	All	effects	were	stable	at	6-	and	12-month	follow-up.	Treatment	adherence	was	high,	with	74%	of	the	participants	initiating	work	with	exposure.		










6.1 IS INTERNET-DELIVERED EXPOSURE THERAPY ACCEPTABLE AND 
EFFECTIVE FOR PATIENTS WITH FM? To	answer	this	question	two	studies	were	conducted.	Study	I	involved	the	development	of	the	treatment	manual	and	evaluation	of	its	acceptability	and	preliminary	efficacy.	Study	II	began	with	an	in-depth	inventory	of	experiences	from	therapists	and	participants	from	Study	I,	which	lay	the	foundation	for	an	extensive	revision	of	the	treatment	manual.	The	updated	version,	which	focused	solely	on	exposure	based	on	FM-related	avoidance	behaviors,	was	evaluated	regarding	efficacy	and	long-term	effects	in	a	randomized	controlled	trial.		In	both	Studies	I-II,	73—74%	of	participants	initiated	work	with	exposure,	indicating	that	they	found	the	treatment	acceptable.	Also,	data	attrition	was	low	in	both	studies,	implying	that	participants	in	general	were	not	too	burdened	by	the	weekly	online	assessments.		Comparing	results	from	Study	I	and	II	to	earlier	trials	on	CBT	for	FM,	the	within-group	effects	seen	in	Study	I	were	higher	than	those	reported	in	a	review	on	psychological	treatments	for	FM.132	Moreover,	the	between-group	effect	sizes	on	pain	intensity	(d=0.86),	fatigue	(d=0.88)	and	disability	(d=0.91)	in	Study	II	is	higher	than	the	corresponding	mean	between-group	effect	sizes	reported	in	a	meta-analysis	on	CBT	trials	for	FM	(pain	intensity	d=0.29,	fatigue	d=0.27,	disability	d=0.43),91	but	with	a	therapist	time	of	only	175	minutes	for	a	whole	treatment.	However,	the	studies	included	in	this	meta-analysis91	used	various	control	conditions	(of	which	treatment-as-usual	was	the	dominant	one),	thus,	comparisons	should	be	made	bearing	this	in	mind.	Results	from	Study	II	was	also	slightly	higher	than	the	between-group	effect	sizes	reported	by	other	studies	on	fatigue,	sleep	problems	and	the	risk	difference	(RD)	in	attaining	≥50%	pain	relief	(RD	0.27)	and	a	≥20%	improvement	of	health-related	quality	of	life	(RD	0.31)	in	a	recent	review	and	meta-analysis	on	internet-delivered	psychological	therapies	for	FM	(≥50%	pain	relief	RD	0.10;	≥20%	improvement	of	health-related	quality	of	life	RD	0.22).133		With	the	exception	of	a	recent	Dutch	study,109	results	from	Study	II	are	also	comparable	to	previous	randomized	controlled	trials	of	exposure	therapy	for	other	chronic	pain	
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conditions	(although	it	should	be	noted	that	the	primary	outcome	in	Study	II	differs	from	previous	trials,	i.e.,	by	also	covering	FM	symptoms	other	than	pain	and	pain-related	disability).	As	described	previously	though,	the	iExp	treatment	manual	differ	from	existing	exposure	protocols	for	chronic	pain.	Whereas	in	previous	trials	exposure	is	aimed	to	target	pain-related	fear,	exposure	according	to	iExp	primarily	targets	the	individual’s	symptom-specific	avoidance	behaviors,	and	also	acknowledges	and	emphasizes	the	role	of	covert	avoidance	behaviors.	The	regular	structured	training	in	observing	and	labelling	aversive	bodily	sensations	might	have	helped	the	participants	to	identify	and	prevent	subtle	or	covert	avoidance	behaviors,	thereby	facilitating	the	effects	of	exposure.	In	addition,	the	fact	that	iExp	exercises	also	comprised	interoceptive	exposure	(i.e.,	actively	provoking	aversive	bodily	symptoms)	might	have	helped	to	decrease	symptom-related	distress.	Whether	the	results	would	be	comparable	with	the	treatment	delivered	in	a	face-to-face	setting	remains	an	empirical	question.	However,	the	variability	and	constant	fluctuation	of	symptoms	in	FM	could	pose	a	risk	of	cancelled	appointments	in	face-to-face	therapy,	and	the	flexibility	attained	with	internet	as	treatment	modality	may	therefore	be	beneficial	for	this	patient	group.	Furthermore,	internet-CBT	enables	patients	in	rural	areas	to	access	treatment,	where	availability	to	CBT	therapists	is	mostly	scarce.118	Nonetheless,	internet	as	treatment	modality	is	a	restraining	factor	regarding	generalizability,	since	many	patients	with	FM	suffer	from	cognitive	difficulties134,135	and	thus	migh	perceive	the	amount	of	reading	as	too	demanding.	Internet-delivered	therapy	is	probably	suitable	for	a	subgroup	of	FM	patients,	while	others	might	benefit	more	from	a	face-to-face	format.	All	the	while,	if	some	patients	with	FM	can	be	successfully	treated	with	internet-delivered	therapy,	this	could	help	relieve	the	patient	burden	on	the	healthcare	system	and	thus	facilitate	a	more	efficient	use	of	healthcare	resources.		So,	yes	-	internet-delivered	exposure	therapy	is	acceptable	and	effective	for	a	self-referred	sample	of	FM	patients	when	evaluated	against	a	waitlist	control,	with	promising	results	on	several	outcomes	compared	to	the	majority	of	CBT	protocols	previously	evaluated	for	this	condition.		
6.2 IS EXPOSURE THERAPY FOR FM COST-EFFECTIVE? We	hypothesized	that	iExp	would	be	cost-effective	as	we	assumed	that	the	effects	gained	would	outweigh	the	additional	costs	of	a	low-resource	treatment	of	internet-	CBT.	The	results	indeed	supported	our	hypothesis.	iExp	was	not	only	cost-effective,	but	cost	saving.	For	every	successful	treatment	(i.e.,	a	treatment	responder)	instead	of	a	participant	on	waitlist,	there	was	a	societal	cost	saving	of	US$15,295.	iExp	had	a	100%	probability	of	being	cost-effective	using	a	societal	perspective,	even	with	a	WTP-scenario	of	$0.		
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The	results	from	Study	III	confirms	the	cost	reductions	observed	in	Study	I,	and	are	also	in	line	with	other	cost-effectiveness	analyses	from	other	internet-delivered	psychological	interventions.136	The	findings	from	Study	III	also	extend	previous	findings	regarding	cost-effectiveness	on	CBT	for	FM	by	including	symptom-specific	as	well	as	generic	outcomes,	providing	an	estimate	of	the	treatment	costs	also	in	relation	to	improvement	of	FM	symptoms	in	addition	to	QALYs	gained.	Dose-response	analyses	also	indicate	that	clinical	gains	were	associated	with	decreases	in	societal	costs.			
6.3 CAN WE IDENTIFY VARIABLES THAT MEDIATE TREATMENT 
OUTCOME?  With	Study	II	being	the	first	evaluation	of	exposure	therapy	for	FM,	and	with	a	new	treatment	manual	than	in	previous	trials	investigating	exposure	for	other	chronic	pain	conditions,	the	choice	of	mediators	in	Study	IV	was	explorative.	Since	previous	mediation	studies	from	CBT92	and	ACT93	treatment	for	FM,	as	well	as	exposure	therapy	for	IBS,137,138		points	in	a	direction	where	a	decrease	in	avoidance	mediates	outcome,	we	aimed	to	include	mediators	that	functionally	capture	different	aspects	of	avoidance.			A	somewhat	unexpected	finding	was	that	only	FM-related	avoidance	behavior	displayed	a	unidirectional	relationship	over	time	with	FM	symptoms,	whereas	the	two	other	proposed	mediators	seem	to	be	bidirectionally	related	to	treatment	outcome.	Notably,	all	three	mediators	were	significant	in	both	the	univariate	and	multivariate	mediation	analysis,	implying	that	the	establishment	of	temporality	is	an	important	feature	when	investigating	treatment	mediators.	The	results	in	Study	IV	are	in	line	with	previous	findings,92,93,137,138	and	thus	add	to	the	growing	body	of	research	supporting	avoidance	behavior	as	an	important	treatment	target	in	exposure	treatment	for	chronic	pain	conditions.	The	findings	are	scientifically	relevant	not	only	as	they	provide	support	for	the	theoretical	underpinnings	of	exposure	(i.e.,	learning	theory),	but	also	since	relatively	few	studies	has	been	dedicated	to	the	nature	of	avoidance	behavior	in	chronic	pain	compared	to	e.g.	pain-related	fear.139	From	a	clinical	view,	the	finding	that	reducing	avoidance	behavior	are	key	for	a	successful	treatment	outcome	in	exposure	therapy	might	be	informative	to	clinicians.	In	addition,	the	fact	that	the	results	favor	the	utility	of	exposure	as	a	treatment	for	FM	could	be	motivating	for	patients.			
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6.4 GENERAL METHODOLOGICAL ISSUES 
6.4.1 On pain-related fear The	studies	in	the	present	thesis	did	not	have	fear	of	pain	or	movement	as	an	inclusion	criterion,	as	opposed	to	previous	trials	of	exposure	therapy	for	chronic	pain109-112	where	participants	were	included	based	on	assessments	on	fear	of	pain	(as	measured	by	Photograph	Series	Of	Daily	Activities,	PHODA114)	or	movement	(as	measured	by	Tampa	Scale	for	Kinesiophobia140).	Contrary	to	these	studies,	the	treatment	model	used	in	the	present	thesis	does	not	stipulate	fear	per	se	to	be	the	fueling	factor	in	the	maintenance	process,	partly	because	it	is	our	clinical	impression	that	many	patients	with	FM	generally	do	not	identify	with	being	fearful	of	pain	or	movement.	Furthermore,	a	post-hoc	regression	analysis	using	baseline	value	of	pain-related	distress	(measured	with	Pain	Reactivity	Scale,	PRS127)	and	pre-to	post	change	on	FIQ	showed	that	pain-related	distress	at	baseline	did	not	predict	treatment	outcome	(p=.93,	unpublished	data).	Nevertheless,	since	previous	studies	show	a	relationship	between	pain-related	fear	and	pain	outcomes,59-61	the	studies	in	the	present	thesis	should	ideally	have	included	a	widely	used	measure	of	pain-related	fear	or	pain	catastrophizing	(e.g.,	Pain	Anxiety	Symptoms	Scale-short	version,	PASS-20141	or	Pain	Catastrophizing	Scale,	PCS142)	to	investigate	its	role	in	relation	to	the	effects	of	iExp.		
6.4.2 iExp vs ACT – the same treatment? Some	might	argue	that	the	iExp	and	ACT	share	so	many	characteristics	that	the	similarities	overcome	the	differences.	This	is	a	fair	question	and	warrants	a	discussion.		As	previously	described,	the	manual	in	Study	I	stemmed	partly	from	an	ACT	protocol	and	thus	bear	several	elements	of	ACT.	Although	the	treatment	manual	was	extensively	revised	in	Study	II,	iExp	and	ACT	do	still	share	several	treatment	features.	Exposure,	self-observation	exercises	and	strategies	to	promote	cognitive	entanglement	are	critical	parts	in	both	protocols.	Both	iExp	and	ACT	acknowledge	overt	as	well	as	covert	avoidance	behaviors	as	important	treatment	targets.	Nonetheless	I	would	argue	that	the	treatments	also	appear	quite	distinct	from	one	another,	that	is,	in	terms	of	what	is	delivered	to	the	patient	and	how	this	is	framed.	One	particular	aspect	that	distinguish	the	treatments	is	the	rationale	for	exposure.	In	ACT,	the	concept	of	life	values	plays	an	important	role	and	exposure	focuses	on	behavioral	change	in	line	with	personal	life	values.	Consequently,	participants	are	instructed	to	derive	exposure	exercises	from	one’s	identified	life	values.	The	central	message	to	the	patient	is	that	exposure	aims	to	aid	the	patient	into	living	a	life	with	more	purpose	and	meaning	in	the	presence	of	pain	and	suffering.	In	iExp,	the	key	message	to	the	patient	is	that	structured	and	repeated	exposure	teaches	the	brain	to	be	less	hyper-reactive	to	pain,	which	thereby	might	lead	to	a	decrease	intensity	of	symptoms	and	symptom-related	distress.	The	patients	derive	suitable	exposure	exercises	from	the	identified	symptom-specific	avoidance	behaviors.	That	is,	iExp	do	not	emphasize	the	importance	of	basing	exposure	on	important	life	
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values,	but	rather	merely	‘for	the	sake	of	it’	to	maximize	future	behavioral	flexibility.	For	the	same	reason,	participants	are	encouraged	to	go	‘full	throttle’	in	their	exposure.	The	role	of	life	values	had	a	more	retracted	role	in	iExp,	introduced	at	the	end	of	treatment	as	part	of	maintenance	of	gains	and	relapse	prevention.	The	difference	in	rationales	for	exposure	is	closely	related	to	another	central	distinction	between	iExp	and	ACT,	namely	the	desired	treatment	outcomes.	Whereas	ACT	aims	for	a	valued	living	via	values-driven	behavior,143	iExp	aims	for	reduction	of	FM	symptoms.	Regardless	of	the	various	similarities	and	dissimilarities	of	iExp	and	ACT,	the	active	treatment	mechanism	could	potentially	still	be	the	same	in	the	two	treatments.	This	warrants	more	attention	in	future	research.			
6.5 VALIDITY AND GENERALIZABILITY OF RESULTS Undoubtedly	the	main	factor	affecting	the	generalizability	of	the	results	from	the	studies	in	the	present	thesis	is	the	use	of	a	waitlist	control	in	Study	II.	That	is,	comparisons	to	other	clinical	trials	should	be	made	bearing	in	mind	that	a	waitlist	control	provides	an	advantageous	comparison	for	the	treatment	under	investigation	(i.e.,	inflating	any	favorable	differences	between	the	treatment	group	and	the	control	group).	Also,	without	an	active	treatment	control,	causal	inferences	on	potential	active	treatment	components	should	be	made	with	caution.		The	use	of	self-referral	in	Studies	I	and	II	suggest	that	participants	might	have	been	more	motivated	and	open	to	psychological	treatment,	or	relatively	less	disabled	-	or	both	-	than	a	clinical	sample	recruited	from	a	tertiary	pain	clinic.	Moreover,	the	sample	in	the	current	study	was	relatively	well	educated,	with	35%	stating	≥3	years	of	college	or	university	education.	Post-hoc	analyses	showed	that	level	of	education	(on	a	7-point	Likert	scale)	did	not	predict	treatment	outcome	(defined	as	pre-	to	post	change	score	on	FIQ)(p=.43	[regression	analysis]	vs	p=.39	[non-parametric	trend	test],	unpublished	data),	although	it	should	be	noted	that	this	might	reflect	a	low	variance	in	the	sample	regarding	this	variable.	Nevertheless,	the	sample	in	Study	II	resembled	those	in	previous	CBT	trials	with	consecutive	clinic	patients	regarding	clinical	characteristics	and	FM	symptoms.91	Thus,	we	do	not	believe	that	the	sample	constitutes	a	severe	outlier	in	terms	of	FM	severity.	As	there	was	no	formal	assessment	of	FM	diagnosis	in	Studies	I-II	we	cannot	be	fully	sure	that	all	participants	had	an	FM	diagnosis.	On	the	other	hand,	since	there	is	yet	no	international	consensus	on	diagnostic	criteria	in	the	clinical	context	the	sample	in	Studies	I-II	probably,	at	least	to	some	degree,	reflect	the	FM	population	seen	in	regular	healthcare.	The	procedure	where	participants	confirm	having	received	a	diagnosis	from	a	physician	has	previously	been	used	successfully	in	several	randomized	controlled	trials	on	CBT	for	adults	with	IBS.105,128,129	In	the	present	PhD	project,	this	approach	
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empowered	a	large-scale	trial	with	participants	from	all	over	Sweden,	generating	well-powered	data	for	a	first	evaluation	of	the	treatment’s	efficacy.		Concerning	the	generalizability	of	the	results	to	other	chronic	pain	conditions,	there	are	no	obvious	reasons	to	believe	that	the	overall	treatment	model	of	iExp	would	not	be	efficacious	for	other	populations	of	chronic	pain.	Notably,	since	the	iExp	manual	is	written	to	be	tailored	to	the	FM	population,	self-help	texts,	case	illustrations	and	worksheet	examples	are	all	written	to	be	identifiable	from	the	perspective	of	an	FM	patient.	Evaluating	iExp	on	a	sample	of	patients	with	i.e.,	low	back	pain,	would	therefore	require	an	extensive	revision	of	the	treatment	manual	regarding	content.	Although	this	remains	an	empirical	question,	a	potential	hypothesis	is	that	the	specific	focus	on	the	symptomatology	and	characteristics	of	FM	might	have	been	experienced	as	positive	by	the	participants,	as	it	might	have	promoted	feelings	of	identification	and	validation.		With	Study	IV	being	an	explorative	investigation	of	mediators	of	outcome,	a	potential	limitation	is	that	we	did	not	include	a	measure	of	hypervigilance	to	pain	as	a	potential	mediator.	Since	hypervigilance	is	a	common	feature	in	patients	with	FM	it	would	have	served	as	a	natural	competitor.	A	more	advanced	statistical	analysis	(i.e.,	structural	equation	modelling)	could	also	have	provided	an	investigation	of	how	the	process	of	excessively	attending	to	bodily	symptoms	relates	to	avoidance	behavior.		
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